Ben Porebski, an Investigator Scientist in Philipp Holliger’s group in the LMB’s PNAC Division, discusses his career so far, including how Australia’s Commonwealth Scientific and Industrial Research Organisation’s (CSIRO) Undergraduate Research Opportunity Program (UROP) allowed him to pursue his passion for research. More…
LMB In The News
Andrew Beale announced a Public Outreach Fellow for the Society for Research on Biological Rhythms
Andrew Beale, a postdoc in John O’Neill’s group in the LMB’s Cell Biology Division, discusses his plans as new Public Outreach Fellow for the Society for Research on Biological Rhythms (SRBR), how a serendipitous lab visit during his PhD got him hooked on circadian rhythms and his hobbies when he’s away from work. More…
Greg Winter on innovation in science, his research on phage display and its therapeutic impact, and winning the Nobel Prize
Roger Highfield, Science Director at the Science Museum, speaks to the LMB’s Greg Winter about his earliest scientific memories, how a road rage attack redirected his research to focus on protein engineering of antibodies and the day he found out he’d won the Nobel Prize in Chemistry. More…
Redefining human brain temperature and its clinical utility
Magnetic resonance spectroscopy allowed Nina Rzechorzek (member of the O’Neill group, Cell Biology) and collaborators to create a HEATWAVE map, showing how temperatures vary in the brain across the day, between the sexes, and as we age – a healthy brain is remarkably hotter than previously assumed. More…
Michel Goedert discusses his life and career in research with DZNE
To mark the award of the Hartwig Piepenbrock-DZNE Prize for his ground-breaking research into the molecular basis of neurodegenerative diseases, DZNE have released a video portrait of Michel Goedert, Group Leader in the LMB’s Neurobiology Division. More…
LMB in vitro testing highlights bicyclic peptides (Bicycle®) as potential antiviral compounds against SARS-CoV-2
Bicycle Therapeutics reports on its updated preclinical data produced in collaboration with Leo James’ group in the LMB’s PNAC Division. In vitro tests of their proprietary bicyclic peptide show promise for antiviral modality against SARS-CoV-2. More…